Citations

Clear

3942 citation(s) found for "To, Van".

P3–159: MAPT H1 subhaplotyping in european PD association samples implicates tau splicing in early–onset parkinson's disease susceptibility
Rademakers, Rosa , Pals, Philippe, Lohmann, Ebba , Engelborghs, Sebastiaan , Pooter, Tim De , Broeck, Marleen Van den , Pickut, Barbara , Cruts, Marc , Deyn, P. De, Sleegers, Kristel , Nuytemans, Karen , Dürr, Alexandra , Farrer, Matthew J. , Brice, Alexis , Broeckhoven, Christine Van

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_14 | Pages: No page available

10.1016/j.jalz.2006.05.1427 Get It

Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications
González-Paz, Natalia, McClure, Rebecca F., Blood, Emily, Oken, Martin M., Ness, Brian Van, James, C. David , Kurtin, Paul J. , Henderson, Kimberly J., Ahmann, Gregory , Lacy, Martha Q. , Dispenzieri, Angela , Greipp, Philip R., Fonseca, Rafaël , Chng, Wee Joo , Gertz, Morie A. , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | July 14, 2006 | Volume: 109 | Issue: 3 | Pages: 1228-1232

10.1182/blood-2006-05-024661 | PMID 16840723 Get It

Abstract The biological and clinical implications of p16 gene methylation in multiple myeloma (MM) are still unclear despite previous studies. In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n = 17), smoldering multiple myeloma (SMM; n = 40), and MM (n = 522) at a prevalence of 24%, 28%, and 34%, respectively. However, p16 methylation does not appear to affect gene expression level. In a large cohort of patients with long-term follow-up information (n = 439), there was no difference in overall survival between patients with or without p16 methylation. We also found no association between p16 methylation and the main cytogenetic categories, although it was more common among patients with 17p13.1 deletions (p53 locus), a genetic progression event in MM. In addition, p16 methylation has no apparent effect on the cycle because there was also no difference in the plasma cell labeling index (a direct measurement of proliferation) between patients with and without p16 methylation. Our results question a major role for p16 methylation in the oncogenesis of the PC neoplasm, and we now believe p16 methylation may be a marker for overall epigenetic changes associated with disease progression, with no obvious direct biological or clinical consequences.
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
Assche, Gert Van , Sandborn, William J. , Feagan, Brian G. , Salzberg, Bruce, Silvers, David, Monroe, Paul S., Pandak, William M. , Anderson, Frank , Valentine, John F. , Wild, Gary , Geenen, Daniel J., Sprague, Rebecca , Targan, Stephan R. , Rutgeerts, P., Vexler, Vladimir, Young, David M., Shames, Richard

Mayo Clinic

Gut | April 7, 2006 | Volume: 55 | Issue: 11 | Pages: 1568-1574

10.1136/gut.2005.089854 | PMID 16603634 Get It

Background: An uncontrolled pilot study demonstrated that daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), might be effective for the treatment of active ulcerative colitis. Methods: A randomised, double blind, placebo controlled trial was conducted to evaluate the efficacy of daclizumab induction therapy in patients with active ulcerative colitis. A total of 159 patients with moderate ulcerative colitis were randomised to receive induction therapy with daclizumab 1 mg/kg intravenously at weeks 0 and 4, or 2 mg/kg intravenously at weeks 0, 2, 4, and 6, or placebo. The primary end point was induction of remission at week 8. Remission was defined as a Mayo score of 0 on both endoscopy and rectal bleeding components and a score of 0 or 1 on stool frequency and physician’s global assessment components. Response was defined as a decrease from baseline in the Mayo score of at least 3 points. Results: Two per cent of patients receiving daclizumab 1 mg/kg (p = 0.11 v placebo) and 7% of patients receiving 2 mg/kg (p = 0.73) were in remission at week 8, compared with 10% of those who received placebo. Response occurred at week 8 in 25% of patients receiving daclizumab 1 mg/kg (p = 0.04) and in 33% of patients receiving 2 mg/kg (p = 0.30) versus 44% of those receiving placebo. Daclizumab was well tolerated. The most frequently reported adverse events in daclizumab treated patients compared with placebo treated patients were nasopharyngitis (14.6%) and pyrexia (10.7%). Conclusion: Patients with moderate ulcerative colitis who are treated with daclizumab are not more likely to be in remission or response at eight weeks than patients treated with placebo.
Dietary Carotenoids and Risk of Lung Cancer in a Pooled Analysis of Seven Cohort Studies
Männistö, Satu , Smith‐Warner, Stephanie A. , Anderson, Kristin E. , Brandt, Piet A. van den , Cerhan, James R. , Colditz, Graham A. , Feskanich, Diane , Freudenheim, Jo L. , Giovannucci, Edward L. , Goldbohm, R. Alexandra, Graham, Saxon, Miller, Anthony B. , Rohan, Thomas E. , Virtamo, Jarmo, Spiegelman, Donna , Albanes, Demetrius , Willett, Walter C. , Hunter, David J. , Cerhan, James R , Colditz, Graham A

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 22, 2006 | Volume: 13 | Issue: 1 | Pages: 40-48

10.1158/1055-9965.epi-038-3 | PMID 14744731 Get It

Abstract Intervention trials with supplemental β-carotene have observed either no effect or a harmful effect on lung cancer risk. Because food composition databases for specific carotenoids have only become available recently, epidemiological evidence relating usual dietary levels of these carotenoids with lung cancer risk is limited. We analyzed the association between lung cancer risk and intakes of specific carotenoids using the primary data from seven cohort studies in North America and Europe. Carotenoid intakes were estimated from dietary questionnaires administered at baseline in each study. We calculated study-specific multivariate relative risks (RRs) and combined these using a random-effects model. The multivariate models included smoking history and other potential risk factors. During follow-up of up to 7–16 years across studies, 3,155 incident lung cancer cases were diagnosed among 399,765 participants. β-Carotene intake was not associated with lung cancer risk (pooled multivariate RR = 0.98; 95% confidence interval, 0.87–1.11; highest versus lowest quintile). The RRs for α-carotene, lutein/zeaxanthin, and lycopene were also close to unity. β-Cryptoxanthin intake was inversely associated with lung cancer risk (RR = 0.76; 95% confidence interval, 0.67–0.86; highest versus lowest quintile). These results did not change after adjustment for intakes of vitamin C (with or without supplements), folate (with or without supplements), and other carotenoids and multivitamin use. The associations generally were similar among never, past, or current smokers and by histological type. Although smoking is the strongest risk factor for lung cancer, greater intake of foods high in β-cryptoxanthin, such as citrus fruit, may modestly lower the risk.
Adrenal Tumors and Pregnancy
Harrington, Jennifer L., Farley, David R. , Heerden, Jon A. van, Ramin, Kirk D.

Mayo Clinic

World Journal of Surgery | February 17, 2006 | Volume: 23 | Issue: 2 | Pages: 182-186

10.1007/pl00013159 | PMID 9880429 Get It

Early aging–associated phenotypes in Bub3/Rae1 haploinsufficient mice
Baker, Darren J. , Jeganathan, Karthik B. , Malureanu, Liviu, Pérez-Terzic, Carmen, Deursen, Jan M. A. van, Terzic, André , Jeganathan, Karthik B , Baker, Darren J

Mayo Clinic

The Journal of Cell Biology | February 13, 2006 | Volume: 172 | Issue: 4 | Pages: 529-540

10.1083/jcb.200507081 | PMID 16476774 Get It

Aging is a highly complex biological process that is believed to involve multiple mechanisms. Mice that have small amounts of the mitotic checkpoint protein BubR1 age much faster than normal mice, but whether other mitotic checkpoint genes function to prevent the early onset of aging is unknown. In this study, we show that several aging-associated phenotypes appear early in mice that are double haploinsufficient for the mitotic checkpoint genes Bub3 and Rae1 but not in mice that are single haploinsufficient for these genes. Mouse embryonic fibroblasts (MEFs) from Bub3/Rae1 haploinsufficient mice undergo premature senescence and accumulate high levels of p19, p53, p21, and p16, whereas MEFs from single haploinsufficient mice do not. Furthermore, although BubR1 hypomorphic mice have less aneuploidy than Bub3/Rae1 haploinsufficient mice, they age much faster. Our findings suggest that early onset of aging-associated phenotypes in mice with mitotic checkpoint gene defects is linked to cellular senescence and activation of the p53 and p16 pathways rather than to aneuploidy.
Conditional Knockout Mice Reveal Distinct Functions for the Global Transcriptional Coactivators CBP and p300 in T-Cell Development
Kasper, Lawryn H., Fukuyama, Tomofusa , Biesen, Michelle A., Boussouar, Fayçal , Tong, Caili , Pauw, Antoine De , Deursen, Jan M. A. van, Brindle, Paul K. , Murray, Peter J.

Mayo Clinic

Molecular and Cellular Biology | January 20, 2006 | Volume: 26 | Issue: 3 | Pages: 789-809

10.1128/mcb.26.3.789-809.2006 | PMID 16428436 Get It

Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells
Xu, Wu , Fukuyama, Tomofusa , Ney, Paul A., Wang, Demin , Boyd, Kelli L. , Deursen, Jan M. A. van, Brindle, Paul K. , Rehg, Jerold E. , Wang, Demin

Mayo Clinic

Blood | January 20, 2006 | Volume: 107 | Issue: 11 | Pages: 4407-4416

10.1182/blood-2005-08-3263 | PMID 16424387 Get It

AbstractCREB-binding protein (CBP) and its para-log p300 are transcriptional coactivators that physically or functionally interact with over 320 mammalian and viral proteins, including 36 that are essential for B cells in mice. CBP and p300 are generally considered limiting for transcription, yet their roles in adult cell lineages are largely unknown since homozygous null mutations in either gene or compound heterozygosity cause early embryonic lethality in mice. We tested the hypotheses that CBP and p300 are limiting and that each has unique properties in B cells, by using mice with Cre/LoxP conditional knockout alleles for CBP (CBPflox) and p300 (p300flox), which carry CD19Cre that initiates floxed gene recombination at the pro–B-cell stage. CD19Cre-mediated loss of CBP or p300 led to surprisingly modest deficits in B-cell numbers, whereas inactivation of both genes was not tolerated by peripheral B cells. There was a moderate decrease in B-cell receptor (BCR)–responsive gene expression in CBP or p300 homozygous null B cells, suggesting that CBP and p300 are essential for this signaling pathway that is crucial for B-cell homeostasis. These results indicate that individually CBP and p300 are partially limiting beyond the pro-B-cell stage and that other coactivators in B cells cannot replace their combined loss.
Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials
Sylvester, Richard , Meijden, Adrian P.M. van der, Lamm, Donald L.

Mayo Clinic

Journal of Urology | January 18, 2006 | Volume: 168 | Issue: 5 | Pages: 1964-1970

10.1016/s0022-5347(05)64273-5 | PMID 12394686 Get It

Community-Acquired Bacterial Meningitis in Adults
Beek, Diederik van de , Gans, Jan de, Tunkel, Allan R. , Wijdicks, Eelco F. M.

Mayo Clinic

New England Journal of Medicine | January 4, 2006 | Volume: 354 | Issue: 1 | Pages: 44-53

10.1056/nejmra052116 | PMID 16394301 Get It